Greenwood Genetic Center Begins First High-Throughput Drug Screen For Rare Disorder

GREENWOOD, SC – October 30, 2024 – The Greenwood Genetic Center (GGC) is collaborating with Gene Spotlight, a nonprofit medical research and advocacy organization, to perform its first high-throughput drug screen for patients with a specific variant in the gene that causes Mucopolysaccharidosis, type 1 (MPS1) also known as Hurler syndrome, Scheie syndrome, or Hurler-Scheie syndrome.

MPS1 is a rare lysosomal storage disorder caused by the inability of the body’s cells to produce enough of an enzyme called alpha-iduronidase that breaks down harmful substances. The toxic buildup of these substances leads to symptoms including coarsening facial features, hearing loss, skeletal and spinal deformities, cardiac issues, and developmental delays.

GGC researchers will screen approximately 1,800 compounds, most of which already have FDA approval for other purposes, to determine if they increase the activity of the alpha-iduronidase enzyme in cells with an MPS1 variant.

“Through ongoing work to better understand how specific genetic changes cause MPS1, we created cell-based tools that will be used to screen a library of FDA-approved drugs for their ability to increase alpha-iduronidase enzyme activity,” said Rich Steet, PhD, Director of Research at GGC. “We are hopeful that of the compounds we screen, we will find a few hits to pursue further as a potential therapy.”

The team identifies a hit as a drug that improves enzyme activity by 25% or more.

“For many of these lysosomal storage disorders, we can see significant clinical improvements with even a small increase in enzyme activity,” added Steet. “If we can go from 1-2% activity to 10-15% activity, that could be life-changing for these patients and their families.”

The project is being funded by Gene Spotlight, a family-led organization committed to sparking breakthroughs in treatments and cures for rare genetic disorders, including lysosomal storage disorders and other rare diseases. Currently, 95% of rare diseases have no approved treatment.

“By screening so many compounds that already have FDA approval, we can potentially identify an effective treatment that we could pull off the shelf and administer immediately,” said Mike Lyons, MD, Curry Chair in Translational Genomics and Therapeutics at GGC. “We are excited for the potential that this and future drug screens can have to improve the quality of life for patients with rare diseases.”

About Greenwood Genetic Center

The Greenwood Genetic Center (GGC), founded in 1974, is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects.  At its home campus in Greenwood, South Carolina, a talented team of physicians and scientists provides clinical genetic services, diagnostic laboratory testing, educational programs and resources, and research in the field of medical genetics.  GGC’s faculty and staff are committed to the goal of developing preventive and curative therapies for the individuals and families they serve.  GGC extends its reach as a resource to all residents of South Carolina with satellite offices in Charleston, Columbia, Florence, and Greenville. For more information about GGC please visit www.ggc.org.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.